Why These 10 Stocks Are Moving Today: November 2, 2026

The market is seeing intense activity today, led by Inovio Pharmaceuticals, Inc. following a landmark regulatory approval. Investors are also reacting to acquisition news and sector-specific catalysts, driving high-volume surges across a diverse group of stocks. Here is a breakdown of why these 10 stocks are moving today.

INO (Inovio Pharmaceuticals, Inc.) — up 229.5% Inovio Pharmaceuticals, Inc. is the day's standout performer after receiving U.S. FDA accelerated approval for VOCERYQ, the first plasmid DNA-based immunotherapy authorized in the United States. The treatment is designed to reduce the frequency of surgical interventions in adults with recurrent respiratory papillomatosis. The move began early in the session, supported by a massive volume surge of 40.7x its 3-month average. Investors are watching for the company's commercial launch plans, expected in early 2027.

INLF (INLIF Limited) — up 64.7% INLIF Limited is seeing significant intraday volatility with a 64.7% move on 421.51M volume, representing 56.8x its normal activity. The surge appears driven by unusual market interest, though no specific company-issued press release has been identified as the primary catalyst. Watch for potential regulatory filings or corporate updates that may clarify this sudden interest.

CLRO (ClearOne, Inc.) — up 58.6% ClearOne, Inc. shares are climbing 58.6% on 38.10M volume, which is 8.9x the stock's 3-month average. The move reflects heightened momentum in the small-cap space. Investors should monitor the company for any upcoming operational updates or contract announcements that could sustain this price action.

EVGO (EVgo, Inc.) — up 49.6% EVgo, Inc. is moving sharply following reports that LS Power Equity Advisors has proposed acquiring the remaining Class A shares of the company. The stock saw a 49.6% jump on 68.01M volume, or 18.5x its average. With Q3 2026 earnings results scheduled for November 9, market participants are closely watching for further details on the acquisition offer.

SEGG (Sports Entertainment Gaming Global Corporation) — up 46.1% Sports Entertainment Gaming Global Corporation experienced a massive volume spike of 477x its 3-month average, driving a 46.1% gain. This extreme liquidity suggests significant institutional or retail interest. Investors should watch for any news regarding partnerships or expansion plans in the gaming sector.

NMRA (Neumora Therapeutics, Inc.) — up 37.7% Neumora Therapeutics, Inc. is up 37.7% on 3.92M volume. The stock has been ranked among the top movers in the full tracked universe today. Watch for any clinical trial updates or pipeline developments that may be fueling this momentum.

ATII (Archimedes Tech SPAC Partners II Co) — up 36.8% Archimedes Tech SPAC Partners II Co is trading up 36.8% on 214.5K volume. As a SPAC, the stock is sensitive to news regarding potential merger targets or business combination updates. Investors should monitor for any definitive agreement announcements.

ADIL (Adial Pharmaceuticals, Inc.) — up 36.1% Adial Pharmaceuticals, Inc. shares rose 36.1% on 83.1K volume. The stock is currently seeing high interest relative to its recent trading range. Watch for any updates regarding the company's clinical programs or regulatory status.

GNTA (Genenta Science S.p.A.) — up 33.0% Genenta Science S.p.A. is up 33.0% on 1.49M volume, which is 28.1x its 3-month average. The biotech firm is seeing unusual intraday activity. Investors should keep an eye on the company's research pipeline and any upcoming data presentations.

PERI (Perion Network Ltd.) — up 31.2% Perion Network Ltd. is surging 31.2% following the announcement that Affle has entered into a definitive merger agreement to acquire the company. The move is supported by 7.31M in volume, 18.6x the 3-month average. Investors are watching for the go-shop deadline and further details on the acquisition timeline.

What Other Outlets Are Reporting * MarketBeat on Inovio's FDA approval. * Business Wire on the Perion-Affle merger agreement. * Marketscreener on the LS Power acquisition offer for EVgo.

Key Takeaways * Inovio Pharmaceuticals leads the market today following the FDA's accelerated approval of its DNA-based immunotherapy, VOCERYQ. * Acquisition news is a major theme, with both EVgo and Perion Network seeing significant price appreciation on buyout-related developments. * Unusual volume spikes across multiple tickers, particularly in SEGG and INLF, indicate high levels of speculative interest in the current session. * Investors should remain cautious of high volatility in these names and monitor for official company filings to confirm the drivers behind these moves. Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.